HE@Cam seminar: Mark Connolly - The public economics consequences of health and investments in healthcare

Add to your list(s) Download to your calendar using vCal

• Mark Connolly
• Monday 16 April 2018, 15:00-16:00
• Large Seminar Room, 1st Floor, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge.

If you have a question about this talk, please contact Patricia Peinado - Assistant Professor.

This talk has been canceled/deleted

Health Economics @ Cambridge welcomes Mark Connolly for the seminar: The public economics consequences of health and investments in healthcare: A government perspective framework. During the seminar, Mark will present his work on how to estimate wider costs to Governments arising from ill health.

Time: 15:00-16:00, Monday 16th April 2018 Venue: Large Seminar Room, 1st Floor, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge

Information can also be found at HE@Cam’s website

About the seminar: Changes in health status have economic costs that can extend beyond the health service. Previous studies have indicated that poor health in working aged adults, and similarly with children who represent future workers, represent the major costs of ill-health to government. For example, a study by the UK government reported non-health costs £62-76 billion annually (2007) of which £29 billion was workless benefits and £28-36 billion in lost tax revenue from poor health. The health sector costs included in typical NICE type cost-effectiveness analysis represented only 8-15% of total government costs. These figures suggest a “government perspective” framework that accounts for transfer costs and lost tax revenues might be more suitable for informing the benefits of healthcare in tax finance public health systems. To address the value of health and healthcare investments for government, we have developed a fiscal health analytic framework that captures how changes in morbidity and mortality influence tax revenue and transfer costs (e.g. disability, allowances, ongoing health costs). The framework can be used to evaluate the marginal impact of discrete investments in healthcare or a mix of interventions to inform governmental budgetary consequences. In this context, the framework can be considered as a fiscal budget impact, and/or cost-benefit analysis model that accounts for how morbidity and mortality linked to specific programs represent both ongoing costs and tax revenue for government. Several examples applying the public economic impact of vaccines, women’s health, and behavioral disorders will be discussed. Applications of the fiscal modelling approach will be discussed and implications for allocation decisions based on public economic consequences and priority setting will be discussed.

Mark Connolly: Mark is the Managing Director at Global Market Access Solutions, with more than 18 years of commercial experience in product reimbursement, technology assessment, market access and pricing. Prior to founding GMAS , Mark held pharmaceutical positions in Australia, and global positions in UK and Switzerland. Mark holds a guest lecturer position at the Pharmacoepidemiology and Pharmacoeconomics Department of the University of Groningen in the Netherlands. He has published over 30 peer-reviewed articles and has had his work reported in major print, television and internet media, including the BBC , Newsweek and the Economist.

All welcome. Part of the HE@Cam 2017-18 series. For any questions, please contact: healtheconomics@medschl.cam.ac.uk

This talk is part of the Health Economics @ Cambridge series.

This talk is included in these lists:

This talk is not included in any other list

Note that ex-directory lists are not shown.